by Jessica Emmerson | Jun 6, 2024 | Research, Study results
BSRBR-RA study blog BSRBR-RA Study website 🔗 We are happy to share our latest research findings: ‘Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying antirheumatic drugs: does line of therapy...
by Jessica Emmerson | May 23, 2024 | Biologic Therapy, Research
Lianne, you did the research, tell us about yourself… Hello, my name is Lianne, I am an epidemiologist at the University of Manchester. For the past 12 years I have been a researcher working on the BSRBR-RA study. In addition, I also have a research interest in the...
by Jessica Emmerson | May 16, 2024 | Associate principal investigator scheme
The BSRBR-RA Study (UK CRN ID: 7302) is part of the NIHR Associate Principal Investigator Scheme. We asked George Nowell, a rheumatology speciality trainee at Stockport NHS Foundation Trust, about his experience as an associate principal investigator on the BSRBR-RA,...
by Jessica Emmerson | Apr 16, 2024 | Uncategorised
BSRBR-RA study blog BSRBR-RA Study website 🔗 We are thrilled to extend a warm invitation to join our sessions at the BSR’s Rheumatology conference. Held between 24th – 26th April 2024 at the ACC in Liverpool, this conference promises a wide variety of talks across all...
by Jessica Emmerson | Apr 10, 2024 | Biologic Therapy, Rheumatoid Arthritis
BSRBR-RA study blog BSRBR-RA Study website 🔗 What is Tyenne? Tyenne is the first tocilizumab (interleukin-6) biosimilar that has recently been approved by the European Medicines Agency (EMA) for the treatment of moderate to severe rheumatoid arthritis in adults. It...
Recent Comments